[go: up one dir, main page]

MX343689B - Formulaciones combinadas de darunavir. - Google Patents

Formulaciones combinadas de darunavir.

Info

Publication number
MX343689B
MX343689B MX2013015199A MX2013015199A MX343689B MX 343689 B MX343689 B MX 343689B MX 2013015199 A MX2013015199 A MX 2013015199A MX 2013015199 A MX2013015199 A MX 2013015199A MX 343689 B MX343689 B MX 343689B
Authority
MX
Mexico
Prior art keywords
darunavir
combination formulations
formulations
combination
solvate
Prior art date
Application number
MX2013015199A
Other languages
English (en)
Other versions
MX2013015199A (es
Inventor
Eugeen Maria Jozef Jans
Philip Erna H Heyns
Roel Jos M Mertens
Der Avoort Geert Van
Urbain Alfons C Delaet
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2013015199A publication Critical patent/MX2013015199A/es
Publication of MX343689B publication Critical patent/MX343689B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a formas sólidas de dosificación oral del inhibidor de VIH darunavir y/o una sal o solvato farmacéuticamente aceptable del mismo, y formulaciones de combinación de las mismas.
MX2013015199A 2011-07-07 2012-07-06 Formulaciones combinadas de darunavir. MX343689B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (2)

Publication Number Publication Date
MX2013015199A MX2013015199A (es) 2014-09-01
MX343689B true MX343689B (es) 2016-11-16

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015199A MX343689B (es) 2011-07-07 2012-07-06 Formulaciones combinadas de darunavir.

Country Status (24)

Country Link
US (3) US20140142070A1 (es)
EP (1) EP2729130B1 (es)
JP (1) JP6122427B2 (es)
KR (1) KR102058097B1 (es)
CN (1) CN103826616B (es)
AU (1) AU2012280198B2 (es)
BR (1) BR112014000290B1 (es)
CA (1) CA2838659C (es)
CY (1) CY1121999T1 (es)
DK (1) DK2729130T3 (es)
EA (1) EA026587B1 (es)
ES (1) ES2651212T3 (es)
HR (1) HRP20171889T1 (es)
HU (1) HUE035241T2 (es)
IL (1) IL229933A (es)
LT (1) LT2729130T (es)
MX (1) MX343689B (es)
NO (1) NO2729130T3 (es)
PL (1) PL2729130T3 (es)
PT (1) PT2729130T (es)
RS (1) RS56667B1 (es)
SI (1) SI2729130T1 (es)
SM (1) SMT201700574T1 (es)
WO (1) WO2013004818A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2729130T1 (en) 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
US20150045366A1 (en) * 2012-03-01 2015-02-12 Gilead Sciences, Inc. Spray dried formulations
KR20230061576A (ko) 2012-12-21 2023-05-08 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
PT3346995T (pt) 2015-11-09 2019-11-22 Gilead Sciences Inc Composições terapêuticas para o tratamento do vírus da imunodeficiência humana
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
EP3496710A4 (en) * 2016-08-08 2020-03-18 Hetero Labs Limited TABLET COMPOSITION WITH A HIGH ACTIVE SUBSTANCE LOAD FOR TREATING HIV
EP3518935A1 (en) * 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
BR112020000842A2 (pt) * 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
US20200101093A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV
US20210290590A1 (en) 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
MY146506A (en) 2006-05-30 2012-08-15 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
BRPI0714055B8 (pt) 2006-07-07 2021-05-25 Gilead Sciences Inc compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
AU2007308986A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
SG183059A1 (en) 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
WO2009000853A2 (en) 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Ltd. Combination formulations comprising darunavir and etravirine
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
EA018582B1 (ru) 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
EP2296633B1 (en) * 2008-05-02 2015-09-30 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
KR101645759B1 (ko) * 2009-02-06 2016-08-04 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
DK2477992T3 (en) * 2009-09-17 2017-03-27 Mylan Laboratories Ltd PROCEDURES FOR PREPARING DARUNAVIR AND ITS AMORPHIC FORM
US20130195978A1 (en) 2010-05-10 2013-08-01 Hetero Research Foundation Darunavir Compositions
CN103841962B (zh) 2011-07-07 2016-08-17 爱尔兰詹森科学公司 地瑞纳韦配制品
SI2729130T1 (en) 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
US20170348334A1 (en) 2015-01-03 2017-12-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Also Published As

Publication number Publication date
CA2838659A1 (en) 2013-01-10
BR112014000290B1 (pt) 2022-05-10
KR20140068845A (ko) 2014-06-09
IL229933A (en) 2017-09-28
HUE035241T2 (en) 2018-05-02
CN103826616A (zh) 2014-05-28
CA2838659C (en) 2020-02-18
ES2651212T3 (es) 2018-01-25
JP2014520787A (ja) 2014-08-25
EP2729130A1 (en) 2014-05-14
DK2729130T3 (en) 2017-12-11
EP2729130B1 (en) 2017-09-06
US20140142070A1 (en) 2014-05-22
PT2729130T (pt) 2017-12-13
US11654150B2 (en) 2023-05-23
SI2729130T1 (en) 2018-03-30
WO2013004818A1 (en) 2013-01-10
LT2729130T (lt) 2018-01-10
PL2729130T3 (pl) 2018-02-28
AU2012280198A1 (en) 2014-01-09
NO2729130T3 (es) 2018-02-03
RS56667B1 (sr) 2018-03-30
US20230302024A1 (en) 2023-09-28
AU2012280198A8 (en) 2014-01-16
EA026587B1 (ru) 2017-04-28
US20200093840A1 (en) 2020-03-26
BR112014000290A2 (pt) 2017-02-07
JP6122427B2 (ja) 2017-04-26
MX2013015199A (es) 2014-09-01
EA201490222A1 (ru) 2014-04-30
HRP20171889T1 (hr) 2018-01-12
SMT201700574T1 (it) 2018-01-11
CY1121999T1 (el) 2020-07-31
CN103826616B (zh) 2016-08-10
KR102058097B1 (ko) 2019-12-20
AU2012280198B2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
MX343689B (es) Formulaciones combinadas de darunavir.
MX341976B (es) Formulaciones de darunavir.
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2014DN10670A (es)
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2013008737A (es) Formas de dosificacion oral para tasocitinib que comprende liberacion modificada.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX348823B (es) Formulaciones estables de linaclotida.
MX2013004190A (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
MY187718A (en) Pharmaceutical formulations
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
TN2015000135A1 (en) Modified release formulations for oprozomib
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
PH12013500210A1 (en) Highly crystalline valsartan
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2012139074A3 (en) Migrastatins and uses thereof
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX2013008559A (es) Derivados de leptina.
MX2011009844A (es) Composicion farmaceutica que comprende alisquireno.
PH12012000220A1 (en) Solid pharmaceutical composition for buccal administration of agomelatine

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: GILEAD SCIENCES, INC.

FG Grant or registration